CureVac, once a player in the Covid-19 vaccine race, announced that it plans to reduce costs across the company.
CureVac N.V., a global biopharmaceutical company developing a new class of medicines based on messenger ribonucleic acid (mRNA), and The University of Texas MD Anderson Cancer Center entered a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
Compared with approved products, the multivalent mRNA vaccine generated superior antibody titers against influenza A strains, but not against B strains.